ArriVent BioPharma, Inc. Common Stock (AVBP)vsEli Lilly and Company (LLY)
AVBP
ArriVent BioPharma, Inc. Common Stock
$24.89
+2.77%
HEALTHCARE · Cap: $1.10B
LLY
Eli Lilly and Company
$935.58
-1.98%
HEALTHCARE · Cap: $854.31B
Smart Verdict
WallStSmart Research — data-driven comparison
LLY leads profitability with a 31.7% profit margin vs 0.0%. LLY earns a higher WallStSmart Score of 78/100 (B+).
AVBP
Avoid26
out of 100
Grade: F
LLY
Strong Buy78
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for AVBP.
Margin of Safety
+12.7%
Fair Value
$1072.19
Current Price
$935.58
$136.61 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 101 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 44.9%
Revenue surging 42.6% year-over-year
Earnings expanding 51.4% YoY
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 31.5x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : AVBP
The strongest argument for AVBP centers on Debt/Equity.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.7% and operating margin at 44.9%. Revenue growth of 42.6% demonstrates continued momentum.
Bear Case : AVBP
The primary concerns for AVBP are Revenue Growth, EPS Growth, Market Cap.
Bear Case : LLY
The primary concerns for LLY are Debt/Equity, P/E Ratio, Price/Book. A P/E of 41.7x leaves little room for execution misses. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Key Dynamics to Monitor
AVBP profiles as a value stock while LLY is a growth play — different risk/reward profiles.
AVBP carries more volatility with a beta of 1.00 — expect wider price swings.
LLY is growing revenue faster at 42.6% — sustainability is the question.
LLY generates stronger free cash flow (678M), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 26/100), backed by strong 31.7% margins and 42.6% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
ArriVent BioPharma, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
ArriVent BioPharma, Inc. is a specialized biopharmaceutical company committed to advancing innovative therapies aimed at addressing unmet medical needs in oncology and autoimmune disorders. Leveraging proprietary technologies and a solid scientific foundation, the company is developing a diverse pipeline of potential treatment candidates designed to significantly improve patient outcomes. With a strategic emphasis on high-growth sectors within the biopharma industry, ArriVent presents a compelling investment opportunity for institutional investors seeking exposure to transformative healthcare advancements.
Visit Website →Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?